PEMETREXED MARKET ANALYSIS

Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by FDA in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. In 2008, ALIMTA, in combination with cisplatin, was approved as an initial chemotherapy treatment for locally advanced or metastatic NSCLC for patients with nonsquamous histology, and in 2009, ALIMTA was approved as a maintenance therapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).

Market Dynamics

Launch of generic version of pemetrexed in key region is expected to increase affordability of pemetrexed, which in turn is expected to support global pemetrexed market growth over the forecast period.

For instance, in July 2018, STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe.

High prevalence of non-small cell lung cancer and pleural mesothelioma is expected to rise the demand for Pemetrexed for its treatment and support global pemetrexed market growth over the forecast period.

For instance, according to the data published by American Society of Clinical Oncology, in January 2018, in the U.S. around 234,030 adults (121,680 men and 112,350 women) were diagnosed with lung cancer among which non-small cell lung cancer is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer diagnose.

Furthermore, key players in the market are dedicated to expand the indication of its Pemetrexed drugs in order to increase its sale and generate high revenues. For instance, in June 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for a new indication for ALIMTA (pemetrexed for injection) in combination with carboplatin and KEYTRUDA (pembrolizumab) for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status.

Key features of the study:

This report provides in-depth analysis of Pemetrexed market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by leading players
It profiles leading players in the global Pemetrexed market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and Others
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global Pemetrexed market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Pemetrexed market

Detailed Segmentation:

Global Pemetrexed Market, By Strength :

100 mg
500 mg

Global Pemetrexed Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Pemetrexed Market, By Region:

North America

By Strength :

100 mg
500 mg

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

U.S.
Canada

Europe

By Strength :

100 mg
500 mg

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe

Asia Pacific

By Strength :

100 mg
500 mg

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific

Latin America

By Strength :

100 mg
500 mg

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Middle East

By Strength :

100 mg
500 mg

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

GCC
Israel
Rest of Middle East

Africa

By Strength :

100 mg
500 mg

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

Central Africa
South Africa
North Africa

Company Profiles

Eli Lilly and Company *

Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments

Request the sample copy of here:

https://www.coherentmarketinsights.com/insight/request-sample/2458

Download the PDF Brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2458

Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2458

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis

Explore CMI Services here

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: [email protected]

Source:

https://www.coherentmarketinsights.com/market-insight/pemetrexed-market-2458